Home Cart Sign in  
Chemical Structure| 1094873-14-9 Chemical Structure| 1094873-14-9

Structure of JNJ-31020028
CAS No.: 1094873-14-9

Chemical Structure| 1094873-14-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

JNJ-31020028 is a brain-permeable and selective neuropeptide Y receptor antagonist IC50 value of 8.51nM

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of JNJ-31020028

CAS No. :1094873-14-9
Formula : C34H36FN5O2
M.W : 565.68
SMILES Code : O=C(NC1=CC=C(N2CCN(C(C3=CC=CC=C3)C(N(CC)CC)=O)CC2)C(F)=C1)C4=CC=CC=C4C5=CC=CN=C5
MDL No. :MFCD18782744
InChI Key :OVUNRYUVDVWTTE-UHFFFAOYSA-N
Pubchem ID :25134625

Safety of JNJ-31020028

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of JNJ-31020028

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293 cells 1 μM 10 minutes To investigate the inhibitory effect of JNJ-31020028 on NPY-induced IP accumulation Nat Commun. 2021 Feb 2;12(1):737

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Insl5-rtTA×Tet-Cre×Dq mouse model Intraperitoneal injection 20 mg/kg Single dose Blockade of Y2R receptor, abolishing the CNO-dependent reduction in food intake Diabetologia. 2020 Jul;63(7):1396-1407
Male Wistar rats Diet-induced obese (DIO) model Osmotic minipump 2.5 mg/kg/day Daily for 8 weeks JNJ-31020028 prevented liver steatosis (p=0.03) without significant weight loss. Downregulation of hepatic de novo lipogenesis-regulating genes (SREBP1 and MLXIPL) was observed (p≤0.0001). Nutrients. 2024 Mar 21;16(6):904
Mice Acute anorexia model Intraperitoneal injection 10 mg/kg·bw Single administration, observed at 0.5, 1, and 2 hours JNJ-31020028, as an NPY2 receptor antagonist, can attenuate the anorexic response induced by PYY or DON Toxins (Basel). 2021 Jul 22;13(8):512
Mice Ovariectomized mouse model Intraperitoneal injection 10 mg/kg Once daily for eight weeks To evaluate the effect of Y2 receptor antagonism on bone formation, results showed antagonist-treated mice had reduced weight, increased whole-body bone mineral density, increased vertebral trabecular bone volume, connectivity density and trabecular thickness, increased bone volume within femoral trabecular regions, and decreased serum P1NP and CTX-1 levels Neuropeptides. 2018 Feb;67:45-55

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.77mL

0.35mL

0.18mL

8.84mL

1.77mL

0.88mL

17.68mL

3.54mL

1.77mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories